This site is intended for healthcare professionals residing in Canada.
Menu
Close
Menu
Close
Recommendations
SOGC Recommendations
NACI Recommendations
CIQ Recommendations
About RSV
About RSV
Infants at Risk
Individuals ≥ 60 Years of Age
About ABRYSVO
Reconstitution and Storage
Dosing and Administration
Mechanism of Action
Efficacy and Safety Profiles
Clinical Trials
MATISSE Study Design
MATISSE Data
MATISSE Safety Profile
RENOIR Study Design
RENOIR Data
RENOIR Safety Profile
More
Coverage Information
Patient Profiles
FAQ
Resources
ABRYSVO is given as a single dose (0.5 mL) via IM injection only.
Pregnant individuals
Administered intramuscularly in the third trimester of pregnancy (from 32 through 36 weeks’ gestation).
Individuals 60 years of age and older
Dose is administered intramuscularly.
IM: intramuscular
Learn more about respiratory syncytial virus and its impact on high-risk populations.
Investigate ABRYSVO’s efficacy and safety profiles in infants and individuals ≥ 60 years of age.
To report an adverse event, please call 1-866-723-7111
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.